Amgen, Inc.: Drug Recall

Recall #D-0855-2022 · 05/02/2022

Class II: Risk

Recall Details

Recall Number: D-0855-2022
Classification: Class II
Product Type: Drug
Recalling Firm: Amgen, Inc.
Status: Terminated
Date Initiated: 05/02/2022
Location: Thousand Oaks, CA, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 15,823

Reason for Recall

Defective container: loose crimp defect, potential loss of container integrity.

Product Description

MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01

Distribution Pattern

Nationwide in the USA, Egypt and Lithuania.

Other Recalls by Amgen, Inc.

Class II: Risk 02/27/2025

Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.
Class II: Risk 02/27/2025

Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.

View all recalls by Amgen, Inc. →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.